Ohr Pharma plunges as wet-AMD drug fails to meet endpoint
Shares of US biotech firm Ohr Pharmaceutical (Nasdaq: OHRP) plunged as much as 65% to $3.07 in heavy, premarket trade Friday, after the company said a Phase II study of its OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment for the wet form of age-related macular degeneration (wet-AMD) failed to meet its primary endpoint.
Ohr Pharmaceutical, an ophthalmology R&D company, today announced the top-line results from the exploratory Phase II IMPACT study evaluating OHR-102 combination therapy with blockbuster drug Lucentis (ranibizumab injection for the treatment of the wet-AMD.
Study results
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze